ciclesonide (Alvesco) vs fluticasone furoate/umeclidinium/vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

ciclesonide (Alvesco)

Marketed by Azurity Pharmaceuticals and partners

Approved in Asthmasmall molecule (corticosteroid)
Reliable signal

NCT00163397 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial comparing ciclesonide to budesonide, using lung function (FEV1) as the primary endpoint -- a regulator-accepted objective measure for asthma. The trial was designed as a non-inferiority comparison, and the prespecified margin test succeeded, meaning ciclesonide performed comparably to the active comparator on its primary measure.

Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.

Reported efficacy

Change from baseline to Week 16 in FEV1: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone (met)

Result source: NCT00174720

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT02924688 · Phase 3 · completed

This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.

Next expected readout: January 2027 · NCT05757102 (registry estimate)

Reported efficacy

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)

Result source: NCT02924688

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointciclesonide (Alvesco)fluticasone furoate/​umeclidinium/​vilanterol
Severe exacerbations, annualised rate—Not posted · NCT00174720—Trial running · NCT04651777
Trough FEV1, change—Not posted · NCT001747200.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
ACQ-5, change—Not posted · NCT00174720—Trial running · NCT04651777
OCS dose reduction—Not posted · NCT00174720—Trial running · NCT04651777

Severe exacerbations, annualised rate

ciclesonide (Alvesco)
—Not posted · NCT00174720
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777

Trough FEV1, change

ciclesonide (Alvesco)
—Not posted · NCT00174720
fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387

ACQ-5, change

ciclesonide (Alvesco)
—Not posted · NCT00174720
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777

OCS dose reduction

ciclesonide (Alvesco)
—Not posted · NCT00174720
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ciclesonide (Alvesco): 4 of 4 rows · fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricciclesonide (Alvesco)fluticasone furoate/​umeclidinium/​vilanterol
Dropout rate
—a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
11.8%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
7.7%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Discontinued due to AEs
—a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
5.1%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
0.7%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Serious AEs
0%a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
0.8%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
4.4%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Most frequent reported AEs
a
headaches/migraine 23.8% (placebo 22.7%)
respiratory infections 19% (placebo 18.2%)
bilateral otitis media 4.8% (placebo 0%)
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
100/31.25/25 mcgb
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FF 200 ug, UMEC 62.5 ug, VI 25 ug
covid-19 5.7%
nasopharyngitis 4.5%
upper respiratory tract infection 4.5%
NCT04937387 · Phase 3 · Asthma · phase 3
FF 100 ug, UMEC 62.5 ug, VI 25 ug
upper respiratory tract infection 7.8%
covid-19 3.3%
nasopharyngitis 3.3%
NCT04937387 · Phase 3 · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · combination
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · combination
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · combination

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ciclesonide (Alvesco)

Lower Leg Growth Velocity MM Wk 0.23 vs 0.33 Beconase and QVAR mm @ 52wk
absolute value · mm
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
0.23 vs 0.51 placebo mm @ 52wk
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
ACQ -0.76 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy

fluticasone furoate/umeclidinium/vilanterol

FEV1 Trough 0.116 vs 0.121 Fluticasone Furoate [FF] / Vilanterol [VI] L @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · L
NCT04937387 · Phase 3 · Asthma · phase 3
show 5 more results
0.136 vs 0.078 Fluticasone Furoate [FF] / Vilanterol [VI] L @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0.12 vs 0.024 FF/VI L @ 24wk100/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.157 vs 0.024 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.134 vs 0.024 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.168 vs 0.024 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FEV1 Change 3 h 0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcg
absolute change · L
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 3 more results
0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
ACQ-7 -0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · score
NCT04937387 · Phase 3 · Asthma · phase 3
show 1 more result
-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ciclesonide (Alvesco)'s landscape · fluticasone furoate/umeclidinium/vilanterol's landscape